NXX-066 in patients with Alzhemer's Disease: A bridging study

This publication has 11 references indexed in Scilit:

• Defining the Maximum Tolerated Dose: Investigator, Academic, Industry and Regulatory Perspectives
  The Journal of Clinical Pharmacology, 1997
• The Bridging Concept: Optimizing Dose for Phase II/III in Alzheimer's Disease
  Neurodegeneration, 1996
• Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*
  Clinical Pharmacology & Therapeutics, 1996
• The Pharmacotherapy of Alzheimer's Disease Based on the Cholinergic Hypothesis: an Update
  Neurodegeneration, 1995
• Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds
  Journal of Medicinal Chemistry, 1995
• Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study
  European Journal of Clinical Pharmacology, 1995
• Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease*
  Clinical Pharmacology & Therapeutics, 1995
• The Safety and Tolerance of Xanomeline Tartrate in Patients with Alzheimer's Disease
  The Journal of Clinical Pharmacology, 1995
• The Target Population in Phase I Clinical Trials of Cholinergic Compounds in Alzheimer Disease
  Alzheimer Disease & Associated Disorders, 1995
• A new approach to determining cholinesterase activities in samples of whole blood
  Clinica Chimica Acta; International Journal of Clinical Chemistry, 1978